Journal of Movement Disorders

Volume 11(2); May 2018

Review Article

Parkinson’s Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care: Uduak Williams, Oliver Bandmann, Richard Walker; J Mov Disord. 2018;11(2):53-64. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.17028

13,720 View
219 Download
31 Web of Science
34 Crossref

A low prevalence of Parkinson’s disease (PD) has been reported in the Sub-Saharan Africa (SSA) region. The genetic causes and clinical features of PD in this region have been poorly described. Very few reports have examined the availability and access to evidence-based quality care for people living with PD in this region. We reviewed all publications focusing on idiopathic PD from SSA published up to May 2016 and observed a prevalence of PD ranging from 7/100,000 in Ethiopia to 67/100,000 in Nigeria. The most recent community-based study reported a mean age at onset of 69.4 years. The infrequent occurrence of mutations in established PD genes was also observed in the region. Treatments were non-existent or at best irregular. Additionally, there is a lack of well-trained medical personnel and multidisciplinary teams in most countries in this region. Drugs for treating PD are either not available or unaffordable. Large-scale genetic and epidemiological studies are therefore needed in SSA to provide further insights into the roles of genetics and other etiological factors in the pathogenesis of PD. The quality of care also requires urgent improvement to meet the basic level of care required by PD patients.

Citations

Citations to this article as recorded by

The Role of Diet in Parkinson’s Disease
Kira N. Tosefsky, Julie Zhu, Yolanda N. Wang, Joyce S.T. Lam, Amanda Cammalleri, Silke Appel-Cresswell
Journal of Parkinson's Disease.2024; : 1. CrossRef
Advancing genetic testing for neurological disorders in Tanzania: importance, challenges, and strategies for implementation
Mohamed Zahir Alimohamed, Angela Augustine Siima, Mohamed Manji
Frontiers in Neuroscience.2024;[Epub] CrossRef
Epidemiology of Parkinson’s Disease: An Update
Juan R Deliz, Caroline M. Tanner, Paulina Gonzalez-Latapi
Current Neurology and Neuroscience Reports.2024;[Epub] CrossRef
Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies
Bilqis Abiola Lawal, Yusuf Oloruntoyin Ayipo, Abisola Oyindamola Adekunle, Mohammed Otuofu Amali, Umar Muhammad Badeggi, Waleed A. Alananzeh, Mohd Nizam Mordi
Journal of Ethnopharmacology.2023; 300: 115753. CrossRef
Particularités de la Maladie de Parkinson de la personne âgée : expérience du service de gériatrie de Fann à Dakar (Sénégal)
A. Sall, M. Ba, R. Djajheté, D. Ba, S. Zaki, M. Coumé
NPG Neurologie - Psychiatrie - Gériatrie.2023; 23(134): 85. CrossRef
The Gaps and Prospects of Movement Disorders Education and Research in Africa: A Continental Survey
Eman Hamid, Kigocha Okengo, Biniyam A. Ayele, Daniel Gams Massi, Samia Ben Sassi, Houyam Tibar, Sarah Misbah El‐Sadig, Soulaimane Mahoui, Julien Razafimahefa, Ange Eric Kouame‐Assouan, Djibrilla Ben‐Adji, Lengane Y.T. Modeste, Muhyadin Hassan Mohamed, Nes
Movement Disorders.2023; 38(2): 178. CrossRef
Transforming Parkinson's Care in Africa (TraPCAf): protocol for a multimethodology National Institute for Health and Care Research Global Health Research Group project
R. Walker, N. Fothergill-Misbah, S. Kariuki, O. Ojo, R. Cilia, M. C. J. Dekker, O. Agabi, A. Akpalu, F. Amod, M. Breckons, M. Cham, S. Del Din, C. Dotchin, S. Guggsa, J. Kwasa, D. Mushi, F. O. Nwaokorie, T. Park, L. Rochester, J. Rogathi, F. S. Sarfo, A.
BMC Neurology.2023;[Epub] CrossRef
Exploring the levodopa-paradox of freezing of gait in dopaminergic medication-naïve Parkinson’s disease populations
Jamie A. F. Jansen, Tamine T. C. Capato, Sirwan K. L. Darweesh, Egberto R. Barbosa, Rogier Donders, Bastiaan R. Bloem, Jorik Nonnekes
npj Parkinson's Disease.2023;[Epub] CrossRef
Delivery of Allied Health Therapies to People with Parkinson’s Disease in Africa
Roberto Cilia, Marieke C.J. Dekker, Esther Cubo, Mary W. Agoriwo
Journal of Parkinson's Disease.2023; : 1. CrossRef
The intestinal luminal sources of α-synuclein: a gastroenterologist perspective
Aaron Lerner
Nutrition Reviews.2022; 80(2): 282. CrossRef
Surveying Global Availability of Parkinson’s Disease Treatment
Zhao H.K. Goh, Julia L.Y. Cheong, Connie Marras, Caroline M. Tanner, Meike Kasten, Amos D. Korczyn, Lana Chahine, Raymond Lo, Alastair J. Noyce
Journal of Parkinson's Disease.2022; 12(3): 1023. CrossRef
Current Status of Next-Generation Sequencing Approaches for Candidate Gene Discovery in Familial Parkinson´s Disease
Nikita Simone Pillay, Owen A. Ross, Alan Christoffels, Soraya Bardien
Frontiers in Genetics.2022;[Epub] CrossRef
Utility of 18F FDG-PET in Parkinsonism in an African population
Ferzana Hassan Amod, Ahmed Iqbal Bhigjee, Nozipho Nyakale
eNeurologicalSci.2022; 27: 100399. CrossRef
A Narrative Review of Specialist Parkinson’s Nurses: Evolution, Evidence and Expectation
Emma Tenison, Alice James, Louise Ebenezer, Emily J. Henderson
Geriatrics.2022; 7(2): 46. CrossRef
Treatment with bark extracts of Voacanga africana attenuates motor coordination deficit, depressive-like behavior and microglial reaction, in a mouse model of early Parkinson's disease
Salimata Diagne Houndjo, Christophe Melon, Pascal Salin, Abdoulaye Samb, Fatou Bintou Sarr, Lydia Kerkerian-Le Goff, Sylviane Lortet
Phytomedicine Plus.2022; 2(3): 100297. CrossRef
Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson's disease cohort
Douglas P. Loesch, Andrea R.V.R. Horimoto, Elif Irem Sarihan, Miguel Inca-Martinez, Emily Mason, Mario Cornejo-Olivas, Luis Torres, Pilar Mazzetti, Carlos Cosentino, Elison Sarapura-Castro, Andrea Rivera-Valdivia, Angel C. Medina, Elena Dieguez, Victor Ra
Parkinsonism & Related Disorders.2022; 102: 7. CrossRef
The impact of COVID‐19 on patients with neurological disorders and their access to healthcare in Africa: A review of the literature
Olivier Uwishema, Kristian Steen Frederiksen, Inês F. Silva Correia, Ashraf Mahmoud, Helen Onyeaka, Burhan Dost
Brain and Behavior.2022;[Epub] CrossRef
Perspective: Low Risk of Parkinson's Disease in Quasi-Vegan Cultures May Reflect GCN2-Mediated Upregulation of Parkin
Mark F McCarty, Aaron Lerner
Advances in Nutrition.2021; 12(2): 355. CrossRef
A Rapid Motor Task-Based Screening Tool for Parkinsonism in Community-Based Studies
Wendy W. Dlamini, Searles Nielsen, Mwiza Ushe, Gill Nelson, Brad A. Racette
Frontiers in Neurology.2021;[Epub] CrossRef
Parkinson disease-associated cognitive impairment
Dag Aarsland, Lucia Batzu, Glenda M. Halliday, Gert J. Geurtsen, Clive Ballard, K. Ray Chaudhuri, Daniel Weintraub
Nature Reviews Disease Primers.2021;[Epub] CrossRef
Probing the Pre-diagnostic Phase of Parkinson's Disease in Population-Based Studies
Lisanne J. Dommershuijsen, Agnita J. W. Boon, M. Kamran Ikram
Frontiers in Neurology.2021;[Epub] CrossRef
Medicinal plants for anti-neurodegenerative diseases in West Africa
Emmanuel Ayodeji Ayeni, Yuzhou Gong, Hao Yuan, Yikao Hu, Xiaolin Bai, Xun Liao
Journal of Ethnopharmacology.2021; : 114468. CrossRef
Mapping the Diverse and Inclusive Future of Parkinson’s Disease Genetics and Its Widespread Impact
Inas Elsayed, Alejandro Martinez-Carrasco, Mario Cornejo-Olivas, Sara Bandres-Ciga
Genes.2021; 12(11): 1681. CrossRef
Parkinson’s disease – a review of pathogenesis, recent advances in management, and challenges of care in sub-Saharan Africa
Akintomiwa I. Makanjuola, Funmilola T. Taiwo, Joseph O. Yaria, Rufus O. Akinyemi, Adesola Ogunniyi
Journal of Global Medicine.2021; : e35. CrossRef
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
Sara Bandres-Ciga, Monica Diez-Fairen, Jonggeol Jeff Kim, Andrew B. Singleton
Neurobiology of Disease.2020; 137: 104782. CrossRef
Targeted next-generation sequencing identifies novel variants in candidate genes for Parkinson’s disease in Black South African and Nigerian patients
Oluwafemi G. Oluwole, Helena Kuivaniemi, Shameemah Abrahams, William L. Haylett, Alvera A. Vorster, Carel J. van Heerden, Colin P. Kenyon, David L. Tabb, Michael B. Fawale, Taofiki A. Sunmonu, Abiodun Ajose, Matthew O. Olaogun, Anastasia C. Rossouw, Ludo
BMC Medical Genetics.2020;[Epub] CrossRef
Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries
Ali Shalash, Njideka U. Okubadejo, Jacques Doumbe, Oluwadamilola O. Ojo, Eman Hamid, Callixte Kuate, Sara Calvo, Asmaa Helmi, Osigwe P. Agabi, Mohamed Essam, Laura Aguado, Hanan Elrassas, Tamer Roushdy, Caroline M. Tanner, Esther Cubo
Journal of Parkinson's Disease.2020; 10(3): 1113. CrossRef
Parkinson's Disease Research on the African Continent: Obstacles and Opportunities
Marieke C. J. Dekker, Toumany Coulibaly, Soraya Bardien, Owen A. Ross, Jonathan Carr, Morenikeji Komolafe
Frontiers in Neurology.2020;[Epub] CrossRef
Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics
Benedicta Obenewaa Dankyi, Seth Kwabena Amponsah, Grace Lovia Allotey-Babington, Ismaila Adams, Nana Aboadwe Goode, Henry Nettey
Current Therapeutic Research.2020; 93: 100612. CrossRef
Parkinson's disease in Nigeria: A review of published studies and recommendations for future research
Oluwafemi G. Oluwole, Helena Kuivaniemi, Jonathan A. Carr, Owen A. Ross, Matthew O.B. Olaogun, Soraya Bardien, Morenikeji A. Komolafe
Parkinsonism & Related Disorders.2019; 62: 36. CrossRef
Clinical series of Parkinson's disease in KwaZulu-Natal, South Africa: Retrospective chart review
Ferzana Hassan Amod, Ahmed Iqbal Bhigjee
Journal of the Neurological Sciences.2019; 401: 62. CrossRef
Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson’s disease
Nicola du Toit, Riaan van Coller, David G. Anderson, Jonathan Carr, Soraya Bardien
neurogenetics.2019; 20(4): 215. CrossRef
Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease
Njideka U. Okubadejo, Mie Rizig, Oluwadamilola O. Ojo, Hallgeir Jonvik, Olajumoke Oshinaike, Emmeline Brown, Henry Houlden, Hiroyoshi Ariga
PLOS ONE.2018; 13(12): e0207984. CrossRef
Motor Symptoms of Parkinson’s Disease – A Review Literature
Hilda Aboagyewaa Agyekum
Neurophysiology and Rehabilitation.2018; : 38. CrossRef

Original Articles

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial: Aryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeon; J Mov Disord. 2018;11(2):65-71. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.18005

9,319 View
252 Download
11 Web of Science
14 Crossref

Abstract PDF Supplementary Material

Objective
We examined whether amantadine can prevent the development of dyskinesia.
Methods
Patients with drug-naïve Parkinson’s disease (PD), younger than 70 years of age and in the early stage of PD (Hoehn and Yahr scale < 3), were recruited from April 2011 to December 2014. The exclusion criteria included the previous use of antiparkinsonian medication, the presence of dyskinesia, significant psychological disorders, and previous history of a hypersensitivity reaction. Patients were consecutively assigned to one of 3 treatment groups in an open label fashion: Group A-1, amantadine first and then levodopa when needed; Group A-2, amantadine first, dopamine agonist when needed, and then levodopa; and Group B, dopamine agonist first and then levodopa when needed. The primary endpoint was the development of dyskinesia, which was analyzed by the Kaplan-Meier survival rate.
Results
A total of 80 patients were enrolled: Group A-1 (n = 27), Group A-2 (n = 27), and Group B (n = 26). Twenty-four patients were excluded from the analysis due to the following: withdrawal of amantadine or dopamine agonist (n = 9), alternative diagnosis (n = 2), withdrawal of consent (n = 1), and breach in the protocol (n = 12). After exclusion, 5 of the 56 (8.93%) patients developed dyskinesia. Patients in Group A-1 and A-2 tended to develop dyskinesia less often than those in Group B (cumulative survival rates of 0.933, 0.929, and 0.700 for A-1, A-2, and B, respectively; p = 0.453).
Conclusion
Amantadine as an initial treatment may decrease the incidence of dyskinesia in patients with drug-naïve PD.

Citations

Citations to this article as recorded by

Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
Sangmin Park, Jung Hwan Shin, Seung Ho Jeon, Chan Young Lee, Han-Joon Kim, Beomseok Jeon
Journal of Movement Disorders.2023; 16(2): 224. CrossRef
Polypharmazie bei der Behandlung von Parkinsonsymptomen: eine Nutzen-Risiko Abwägung
J. Bedarf, I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
DGNeurologie.2023; 6(6): 504. CrossRef
Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes – a modern state of the problem
Vladimir D. Dergachev, Ekaterina E. Yakovleva, Eugenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov
Reviews on Clinical Pharmacology and Drug Therapy.2022; 20(1): 17. CrossRef
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
Imane Frouni, Woojin Kang, Dominique Bédard, Sébastien Belliveau, Cynthia Kwan, Shadi Hadj-Youssef, Élodie Bourgeois-Cayer, Leanne Ohlund, Lekha Sleno, Adjia Hamadjida, Philippe Huot
European Journal of Pharmacology.2022; 929: 175090. CrossRef
Amantadine in the treatment of Parkinson’s disease. New opportunities in the context of COVID-19
E.A. Katunina
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2021; 121(4): 101. CrossRef
Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska
Journal of Clinical Medicine.2021; 10(19): 4377. CrossRef
Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets
Suraj Sulhan, Kristopher A. Lyon, Lee A. Shapiro, Jason H. Huang
Journal of Neuroscience Research.2020; 98(1): 19. CrossRef
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji
Expert Opinion on Emerging Drugs.2020; 25(2): 131. CrossRef
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD)
Michelle Ann C. Sy, Hubert H. Fernandez
Neurotherapeutics.2020; 17(4): 1331. CrossRef
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Jing Liu, Fei Xu, Zhiyan Nie, Lei Shao
Frontiers in Cellular and Infection Microbiology.2020;[Epub] CrossRef
Viewpoint: Developing drugs for levodopa‐induced dyskinesia in PD: Lessons learnt, what does the future hold?
Susan H. Fox, Jonathan M. Brotchie
European Journal of Neuroscience.2019; 49(3): 399. CrossRef
Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
I. Csoti, H. Herbst, P. Urban, D. Woitalla, U. Wüllner
Journal of Neural Transmission.2019; 126(7): 871. CrossRef
Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G. Nuara, Jim C. Gourdon, Francis Beaudry, Philippe Huot
Neuropharmacology.2019; 158: 107725. CrossRef
Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update
Valentina Leta, Peter Jenner, K. Ray Chaudhuri, Angelo Antonini
Expert Opinion on Drug Safety.2019; 18(12): 1203. CrossRef

Prospective Characterization of Cognitive Function in Typical and ‘Brainstem Predominant’Progressive Supranuclear Palsy Phenotypes: Young-Eun C Lee, David R Williams, Jacqueline F I Anderson; J Mov Disord. 2018;11(2):72-77. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.17067

7,985 View
126 Download
7 Web of Science
7 Crossref

Abstract PDF

Objective
Clinicopathological studies over the last decade have broadened the clinical spectrum of progressive supranuclear palsy (PSP) to include several distinct clinical syndromes. We examined the cognitive profiles of patients with PSP-Richardson’s syndrome (PSP-RS) and two atypical ‘brainstem predominant’ PSP phenotypes (PSP-parkinsonism, PSP-P; and PSP-pure akinesia with gait freezing, PSP-PAGF) using a comprehensive neuropsychological battery.
Methods
Fourteen patients diagnosed as PSP-RS, three patients with PSP-P and four patients with PSP-PAGF were assessed using a comprehensive battery of neuropsychological tests.
Results
The typical PSP-RS subgroup demonstrated greater impairments in processing speed [t(19) = -4.10, p = 0.001 (d =1.66)] and executive function [t(19) = -2.63, p = 0.02 (d = 1.20)] compared to the ‘brainstem predominant’ PSP phenotype.
Conclusion
This is the first prospective study to demonstrate that PSP-RS and ‘brainstem predominant’ PSP phenotypes can be differentiated on cognitive grounds. These differences correspond with variations in pathological profiles reported in the literature.

Citations

Citations to this article as recorded by

Pathomechanisms of cognitive impairment in progressive supranuclear palsy
Kurt A. Jellinger
Journal of Neural Transmission.2023; 130(4): 481. CrossRef
Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes—Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism
Patrycja Krzosek, Natalia Madetko, Anna Migda, Bartosz Migda, Dominika Jaguś, Piotr Alster
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Clinical Spectrum of Tauopathies
Nahid Olfati, Ali Shoeibi, Irene Litvan
Frontiers in Neurology.2022;[Epub] CrossRef
Neuropsychological assessment could distinguish among different clinical phenotypes of progressive supranuclear palsy: A Machine Learning approach
Maria Grazia Vaccaro, Alessia Sarica, Andrea Quattrone, Carmelina Chiriaco, Maria Salsone, Maurizio Morelli, Aldo Quattrone
Journal of Neuropsychology.2021; 15(3): 301. CrossRef
“Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism
Ján Necpál, Miroslav Borsek, Bibiána Jeleňová
Neurological Sciences.2021; 42(12): 4927. CrossRef
The Progressive Supranuclear Palsy: Past and Present Aspects
Theodore P. Parthimos, Kleopatra H. Schulpis
Clinical Gerontologist.2020; 43(2): 155. CrossRef
Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P)—A Clinical Challenge at the Boundaries of PSP and Parkinson's Disease (PD)
Piotr Alster, Natalia Madetko, Dariusz Koziorowski, Andrzej Friedman
Frontiers in Neurology.2020;[Epub] CrossRef

Oromandibular Dystonia: Demographics and Clinical Data from 240 Patients: Linda Slaim, Myriam Cohen, Patrick Klap, Marie Vidailhet, Alain Perrin, Daniel Brasnu, Denis Ayache, Marie Mailly; J Mov Disord. 2018;11(2):78-81. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.17065

7,026 View
226 Download
22 Web of Science
26 Crossref

Abstract PDF

Objective
To report demographic data from a large cohort of patients with oromandibular dystonia (OMD).
Methods
This is a retrospective review of patients with OMD referred to our institution between 1989 and 2015. Demographic (age of onset, gender, and familial history of dystonia) and clinical (type of OMD, associated dystonia, and etiology of dystonia) data were collected from a cohort of 240 individuals.
Results
The mean age of onset of OMD was 51.6 years old, with a female predominance (2:1). A family history of dystonia was found in 6 patients (2.5%). One hundred and forty-nine patients (62.1%) had the jaw-opening type of OMD, 48 patients (20.0%) had the jaw-closing type, and 43 patients (17.9%) had a mixed form of OMD. Lingual dystonia was also present in 64 (26.7%) of these patients. Eighty-two patients (34.2%) had a focal dystonia, 131 patients (54.6%) had a segmental dystonia, and 27 patients (11.3%) had a generalized dystonia. One hundred and seventy-one patients (71.3%) had idiopathic OMD.
Conclusion
OMD is a chronic and disabling focal dystonia. Our study found a prevalence of female patients, an onset in middle age and a predominantly idiopathic etiology. Unlike other studies, jaw-opening was found to be the most frequent clinical type of OMD.

Citations

Citations to this article as recorded by

Surface electromyography for evaluating patients with oromandibular dystonia
Jae-Hyung Kim, Byung-Gook Kim, Yeong-Gwan Im
CRANIO®.2024; 42(3): 316. CrossRef
Tongue dystonia as CIS and presenting symptom of multiple sclerosis
Farid Shamlou, Narges Ebrahimi, Ahmad Chitsaz
Neuroimmunology Reports.2024; 5: 100191. CrossRef
Oromandibular dystonia: from onset to spread a multicenter italian study
Assunta Trinchillo, Marcello Esposito, Carmen Terranova, Vincenzo Rizzo, Giovanni Fabbrini, Gina Ferrazzano, Daniele Belvisi, Roberto Erro, Paolo Barone, Francesco Bono, Francesca Di Biasio, Anna Rita Bentivoglio, Christian Lettieri, Maria Concetta Altavi
Neurological Sciences.2024;[Epub] CrossRef
Oromandibular Dystonia: Clinical and Demographic Data from Eight-Two Patients
Mehmet Balal, Meltem Demirkiran
Tremor and Other Hyperkinetic Movements.2023;[Epub] CrossRef
Oromandibular Dystonia is a Prominent Feature in Patients with Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
Helio van der Linden Jr., Christiane Cobas, Andre Felipe Pinto Duarte, Marcelo Rodrigues Masruha
Journal of Inborn Errors of Metabolism and Screening.2023;[Epub] CrossRef
Clinical Presentation and Management of Peripheral-induced Oromandibular Dystonia in Nigeria: A Case Report and Literature Update
Nonso Emmanuel Onyia, Mercy Okoh, Obinna Francis Igwilo, Izegboya Vivian Ukpebor, Eze Stephen Nwauzor
Nigerian Journal of Medicine.2023; 32(4): 433. CrossRef
Oromandibular dystonia – A systematic review
Udit Saraf, Mitesh Chandarana, KP Divya, Syam Krishnan
Annals of Indian Academy of Neurology.2022; 25(1): 26. CrossRef
Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System
Kazuya Yoshida
Toxins.2022; 14(4): 282. CrossRef
Botulinum toxin injections in jaw-opening dystonia. The lateral pterygoid – maxillary artery problem
Sena Ünal, F. Tugra Karaarslan-Turk, Muhittin Cenk Akbostanci, Elif Peker, Rezzak Yilmaz
Journal of Clinical Neuroscience.2022; 101: 217. CrossRef
Oromandibular dystonia seen during pramipexole treatment: A rare case
Fatma KARA, Mehmet Fatih GÖL, Ayhan VARLIBAŞ
Journal of Surgery and Medicine.2022; 6(6): 1. CrossRef
Dystonia, chorea, hemiballismus and other dyskinesias
Matteo Bologna, Josep Valls-Solè, Nitish Kamble, Pramod Kumar Pal, Antonella Conte, Andrea Guerra, Daniele Belvisi, Alfredo Berardelli
Clinical Neurophysiology.2022; 140: 110. CrossRef
Movement disorders of the mouth: a review of the common phenomenologies
C. M. Ghadery, L. V. Kalia, B. S. Connolly
Journal of Neurology.2022; 269(11): 5812. CrossRef
Botulinum Toxin in Movement Disorders: An Update
Charenya Anandan, Joseph Jankovic
Toxins.2021; 13(1): 42. CrossRef
Temporomandibular disorder–related characteristics and treatment outcomes in Oromandibular Dystonia patients in two different clinical settings: A cross‐sectional study
Asha Sude, Joseph Matsumoto, Shanti Kaimal, Ashley Petersen, Donald R. Nixdorf
Journal of Oral Rehabilitation.2021; 48(5): 542. CrossRef
Jaw Pain and Oromandibular Dysfunction After a Complex Hospital Course
Sarah Smith, Ny-Ying Lam
American Journal of Physical Medicine & Rehabilitation.2021; 100(5): e62. CrossRef
Oromandibular Dystonia: A Clinical Examination of 2,020 Cases
Laura M. Scorr, Stewart A. Factor, Sahyli Perez Parra, Rachel Kaye, Randal C. Paniello, Scott A. Norris, Joel S. Perlmutter, Tobias Bäumer, Tatiana Usnich, Brian D. Berman, Marie Mailly, Emmanuel Roze, Marie Vidailhet, Joseph Jankovic, Mark S. LeDoux, Ric
Frontiers in Neurology.2021;[Epub] CrossRef
Evaluation of Treatment Outcomes in Oromandibular Dystonia Using Surface Electromyography: A Case Series
Yeong-Gwan Im, Jae-Hyung Kim, Byung-Gook Kim
Journal of Oral Medicine and Pain.2021; 46(4): 143. CrossRef
Application of botulinum toxin in pregnancy and its impact on female reproductive health
Wu Li, Min Tang
Expert Opinion on Drug Safety.2020; 19(1): 83. CrossRef
Prevalence and clinical characteristics of patients with oromandibular dystonia seen in the orofacial pain clinic: a retrospective study
Asha Sude, Donald R. Nixdorf
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2020; 130(2): 169. CrossRef
Clinical spectrum of focal dystonias: Experience from a tertiary care center
Rupesh Prasad, Deepika Joshi, VijayN Mishra, RameshwarN Chaurasia, Abhishek Pathak
Annals of Movement Disorders.2020; 3(2): 99. CrossRef
Bite injury related to oromandibular dystonia extending to the maxillary sinus: A case report
Yoshiro Koma, Takehiro Fujimoto, Shinji Uejima, Kotaro Sato, Keisuke Sugimoto, Satoshi Yamaguchi, Jun Ishikawa, Kazuya Nambu, Hideharu Hibi
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2020; 32(6): 503. CrossRef
Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis
Pariessa D. Dadgardoust, Raymond L. Rosales, Ria Monica Asuncion, Dirk Dressler
Journal of Neural Transmission.2019; 126(2): 141. CrossRef
Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features
Kazuya Yoshida
Toxins.2019; 11(1): 51. CrossRef
Oromandibular dystonia, mental distress and oro‐facial dysfunction—A follow‐up 8‐10 years after start of treatment with botulinum toxin
Merete Bakke, Sara Baram, Torben Dalager, Heidi Bryde Biernat, Eigild Møller
Journal of Oral Rehabilitation.2019; 46(5): 441. CrossRef
Pseudodystonia: A new perspective on an old phenomenon
Rok Berlot, Kailash P. Bhatia, Maja Kojović
Parkinsonism & Related Disorders.2019; 62: 44. CrossRef
Severe Jaw‐Opening Dystonia as an Unusual Manifestation of Levodopa‐Related Wearing‐Off in Parkinson's Disease, and Successful Treatment With Botulinum Toxin Injection
Pankaj Ashok Agarwal
Movement Disorders Clinical Practice.2019; 6(6): 500. CrossRef

Case Reports

Transcranial Direct Current Stimulation Combined with Action Observation and Electromyographic Biofeedback Training in a Patient with Writer’s Cramp: Yohei Okada, Chiharu Shibamoto, Yukari Osumi, Chihiro Asano, Riho Takeuchi, Sachio Nabeshima, Shu Morioka, Koji Shomoto; J Mov Disord. 2018;11(2):82-86. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.18007

8,929 View
87 Download
5 Web of Science
5 Crossref

Abstract PDF Supplementary Material

We present a 47-year-old right-handed woman with a 15-year history of writer’s cramp who was provided with six sessions of cathodal transcranial direct current stimulation (tDCS) combined with observation of writing actions performed by a healthy subject and electromyographic (EMG) biofeedback training to decrease EMG activities in her right forehand muscles while writing for 30 min for 4 weeks. She showed improvement in dystonic posture and writing speed after the intervention. The writing movement and writing speed scores on a writer’s cramp rating scale decreased, along with writing time. Our findings demonstrated that cathodal tDCS combined with action observation and EMG biofeedback training might improve dystonic writing movements in a patient with writer’s cramp.

Citations

Citations to this article as recorded by

Effects of non-invasive brain stimulation in dystonia: a systematic review and meta-analysis
Jordan Morrison-Ham, Gillian M. Clark, Elizabeth G. Ellis, Andris Cerins, Juho Joutsa, Peter G. Enticott, Daniel T. Corp
Therapeutic Advances in Neurological Disorders.2022; 15: 175628642211381. CrossRef
New modalities and directions for dystonia care
Genko Oyama, Nobutaka Hattori
Journal of Neural Transmission.2021; 128(4): 559. CrossRef
The Mini-BESTest is an independent predictor of falls in Parkinson Disease
Larissa Karlla Rodrigues Lopes, Aline Alvim Scianni, Lidiane Oliveira Lima, Raquel de Carvalho Lana, Fátima Rodrigues-De-Paula
Brazilian Journal of Physical Therapy.2020; 24(5): 433. CrossRef
Modulating Observation-Execution-Related Motor Cortex Activity by Cathodal Transcranial Direct Current Stimulation
Fengxue Qi, Michael A. Nitsche, Volker R. Zschorlich
Brain Sciences.2019; 9(5): 121. CrossRef
Beyond the target area: an integrative view of tDCS-induced motor cortex modulation in patients and athletes
Edgard Morya, Kátia Monte-Silva, Marom Bikson, Zeinab Esmaeilpour, Claudinei Eduardo Biazoli, Andre Fonseca, Tommaso Bocci, Faranak Farzan, Raaj Chatterjee, Jeffrey M. Hausdorff, Daniel Gomes da Silva Machado, André Russowsky Brunoni, Eva Mezger, Luciane
Journal of NeuroEngineering and Rehabilitation.2019;[Epub] CrossRef

Purposeless Groaning in Parkinson’s Disease: Shen-Yang Lim, Ai Huey Tan, Jia Lun Lim, Azlina Ahmad-Annuar; J Mov Disord. 2018;11(2):87-88. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.18004

7,899 View
109 Download
6 Web of Science
5 Crossref

Abstract PDF Supplementary Material

Purpose
less groaning has been reported in advanced progressive supranuclear palsy. We present a case of purposeless groaning occurring as a primary complaint in a patient with advanced Parkinson’s disease. Purposeless groaning is thought to be a manifestation of disinhibition and perseveration due to frontal-subcortical dysfunction. Proper recognition of this phenomenon will help clinicians to avoid unnecessary investigations and treatment (e.g., prescription of opioid medications).

Citations

Citations to this article as recorded by

OFF-Period Purposeless Groaning in Parkinsonism
Vikash Agarwal, Jeyalakshmi Rajan, Norlisah Ramli, Cecilia Santiago, DushyanthB Jasti, AiHuey Tan, Shen-Yang Lim
Neurology India.2022; 70(3): 1232. CrossRef
Involuntary moaning in a Hispanic family with eight affected members
Maria Gisatulin, Malco Rossi, Claudia Perandones, Christine Klein, Katja Lohmann, Marcelo Merello
Parkinsonism & Related Disorders.2021; 89: 206. CrossRef
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
Jung E. Park
JAMA Neurology.2020; 77(12): 1569. CrossRef
Clinical Phenotype of LRRK2 R1441C in 2 Chinese Sisters
Shen-Yang Lim, Jia Lun Lim, Azlina Ahmad-Annuar, Katja Lohmann, Ai Huey Tan, Kai Bin Lim, Yi Wen Tay, Yee Lee Shing, Kalai Arasu Muthusamy, Peter Bauer, Arndt Rolfs, Christine Klein
Neurodegenerative Diseases.2020; 20(1): 39. CrossRef
The spectrum of involuntary vocalizations in humans: A video atlas
Tina Mainka, Bettina Balint, Felix Gövert, Lille Kurvits, Christoph van Riesen, Andrea A. Kühn, Marina A.J. Tijssen, Andrew J. Lees, Kirsten Müller‐Vahl, Kailash P. Bhatia, Christos Ganos
Movement Disorders.2019; 34(12): 1774. CrossRef

A Patient with Beta-Propeller Protein-Associated Neurodegeneration: Treatment with Iron Chelation Therapy: Shen-Yang Lim, Ai Huey Tan, Azlina Ahmad-Annuar, Susanne A. Schneider, Ping Chong Bee, Jia Lun Lim, Norlisah Ramli, Mohamad Imran Idris; J Mov Disord. 2018;11(2):89-92. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.17082

25,890 View
159 Download
11 Web of Science
12 Crossref

Abstract PDF Supplementary Material

We present a case of beta-propeller protein-associated neurodegeneration, a form of neurodegeneration with brain iron accumulation. The patient harbored a novel mutation in the WDR45 gene. A detailed video and description of her clinical condition are provided. Her movement disorder phenomenology was characterized primarily by limb stereotypies and gait dyspraxia. The patient’s disability was advanced by the time iron-chelating therapy with deferiprone was initiated, and no clinical response in terms of cognitive function, behavior, speech, or movements were observed after one year of treatment.

Citations

Citations to this article as recorded by

Lipid droplet accumulation in Wdr45-deficient cells caused by impairment of chaperone-mediated autophagic degradation of Fasn
Qiuhong Xiong, Huimin Sun, Yanlin Wang, Qian Xu, Yu Zhang, Mei Xu, Zhonghua Zhao, Ping Li, Changxin Wu
Lipids in Health and Disease.2024;[Epub] CrossRef
Quantitative retrospective natural history modeling of WDR45-related developmental and epileptic encephalopathy – a systematic cross-sectional analysis of 160 published cases
Afshin Saffari, Julian Schröter, Sven F. Garbade, Julian E. Alecu, Darius Ebrahimi-Fakhari, Georg F. Hoffmann, Stefan Kölker, Markus Ries, Steffen Syrbe
Autophagy.2022; 18(7): 1715. CrossRef
Cerebral Iron Deposition in Neurodegeneration
Petr Dusek, Tim Hofer, Jan Alexander, Per M. Roos, Jan O. Aaseth
Biomolecules.2022; 12(5): 714. CrossRef
Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders
Rachel M. Wise, Annika Wagener, Urban M. Fietzek, Thomas Klopstock, Eugene V. Mosharov, Fabio A. Zucca, David Sulzer, Luigi Zecca, Lena F. Burbulla
Neurobiology of Disease.2022; 175: 105920. CrossRef
WDR45 variants cause ferrous iron loss due to impaired ferritinophagy associated with nuclear receptor coactivator 4 and WD repeat domain phosphoinositide interacting protein 4 reduction
Kiwako Tsukida, Shin-ichi Muramatsu, Hitoshi Osaka, Takanori Yamagata, Kazuhiro Muramatsu
Brain Communications.2022;[Epub] CrossRef
Iron Chelation in Movement Disorders: Logical or Ironical
Dinkar Kulshreshtha, Jacky Ganguly, Mandar Jog
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2021; : 1. CrossRef
Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders
Vassilena Iankova, Ivan Karin, Thomas Klopstock, Susanne A. Schneider
Frontiers in Neurology.2021;[Epub] CrossRef
Consensus clinical management guideline for beta‐propeller protein‐associated neurodegeneration
Jenny L Wilson, Allison Gregory, Manju A Kurian, Ittai Bushlin, Fanny Mochel, Lisa Emrick, Laura Adang, Penelope Hogarth, Susan J Hayflick
Developmental Medicine & Child Neurology.2021; 63(12): 1402. CrossRef
WDR45, one gene associated with multiple neurodevelopmental disorders
Yingying Cong, Vincent So, Marina A. J. Tijssen, Dineke S. Verbeek, Fulvio Reggiori, Mario Mauthe
Autophagy.2021; 17(12): 3908. CrossRef
Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation
Robert V.V. Spaull, Audrey K.S. Soo, Penelope Hogarth, Susan J. Hayflick, Manju A. Kurian
Tremor and Other Hyperkinetic Movements.2021;[Epub] CrossRef
The roles of iron and HFE genotype in neurological diseases
Yunsung Kim, James R. Connor
Molecular Aspects of Medicine.2020; 75: 100867. CrossRef
The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System
Karina Joppe, Anna-Elisa Roser, Fabian Maass, Paul Lingor
Frontiers in Neuroscience.2019;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Previous issues